Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06632379 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

AtorvaStatin Postpartum and Reduction of Cardiovascular risK

Study acronym: SPARK
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated October 20, 2025 (before its estimated September 15, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Sep 15, 2025 to Oct 3, 2025
    • Site details revised
    • Eligibility criteria shortened, about 5 words
    v6
  2. Start date: May 15, 2025 to Sep 15, 2025
    • Primary completion date: May 15, 2026 to Sep 15, 2026
    v5
  3. Start date: Feb 15, 2025 to May 15, 2025
    • Primary completion date: Feb 15, 2026 to May 15, 2026
    • Study completion date: Oct 15, 2026 to Dec 15, 2026
    v4
  4. Start date: Dec 15, 2024 to Feb 15, 2025
    • Primary completion date: Dec 15, 2025 to Feb 15, 2026
    • Study completion date: Aug 15, 2026 to Oct 15, 2026
    v3
  5. Start date: Oct 15, 2024 to Dec 15, 2024
    • Primary completion date: Oct 15, 2025 to Dec 15, 2025
    • Study completion date: Jun 15, 2026 to Aug 15, 2026
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The objective is to conduct a double-blinded randomized controlled trial of atorvastatin vs. placebo among postpartum individuals with hypertensive disorders of pregnancy, to improve cardiovascular risk score postpartum. For this, 76 individuals with hypertensive disorders of pregnancy (HDP) will be randomized to atorvastatin 10mg or placebo, which will be started in the postpartum period after cessation of breast feeding and continued for 3 months.
Trial Details
NCT Number NCT06632379
Lead Sponsor Ohio State University
Conditions
(from sponsor)		 Hypertensive Disorders of Pregnancy, Preeclampsia, Gestational Hypertension
Related terms Hypertension, Pregnancy-Induced, Pre-Eclampsia
Enrollment 76 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov